High-Throughput Screening Data Interpretation in the Context of In Vivo Transcriptomic Responses to Oral Cr(VI) Exposure

• Published in: Toxicological sciences 2017-07, Vol.158 (1), p.199-212
• Main Authors: Rager, Julia E, Ring, Caroline L, Fry, Rebecca C, Suh, Mina, Proctor, Deborah M, Haws, Laurie C, Harris, Mark A, Thompson, Chad M
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Apoptosis - drug effects; Cell Proliferation - drug effects; Chromium (IV) Exposure and Transcriptomic Screening; Chromium - administration & dosage; Chromium - toxicity; Dose-Response Relationship, Drug; High-Throughput Screening Assays; Mice; Signal Transduction - drug effects; Transcriptome; Tumor Suppressor Protein p53 - metabolism
• ISSN: 1096-6080; 1096-0929
• DOI: 10.1093/toxsci/kfx085

The toxicity of hexavalent chromium [Cr(VI)] in drinking water has been studied extensively, and available in vivo and in vitro studies provide a robust dataset for application of advanced toxicological tools to inform the mode of action (MOA). This study aimed to contribute to the understanding of Cr(VI) MOA by evaluating high-throughput screening (HTS) data and other in vitro data relevant to Cr(VI), and comparing these findings to robust in vivo data, including transcriptomic profiles in target tissues. Evaluation of Tox21 HTS data for Cr(VI) identified 11 active assay endpoints relevant to the Ten Key Characteristics of Carcinogens (TKCCs) that have been proposed by other investigators. Four of these endpoints were related to TP53 (tumor protein 53) activation mapping to genotoxicity (KCC#2), and four were related to cell death/proliferation (KCC#10). HTS results were consistent with other in vitro data from the Comparative Toxicogenomics Database. In vitro responses were compared to in vivo transcriptomic responses in the most sensitive target tissue, the duodenum, of mice exposed to ≤ 180 ppm Cr(VI) for 7 and 90 days. Pathways that were altered both in vitro and in vivo included those relevant to cell death/proliferation. In contrast, pathways relevant to p53/DNA damage were identified in vitro but not in vivo. Benchmark dose modeling and phenotypic anchoring of in vivo transcriptomic responses strengthened the finding that Cr(VI) causes cell stress/injury followed by proliferation in the mouse duodenum at high doses. These findings contribute to the body of evidence supporting a non-mutagenic MOA for Cr(VI)-induced intestinal cancer.